A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis

European Journal of Clinical Investigation

Volumn 45, Issue 12, 2015, Pages 1260-1269

  Müller Deile, Janina ^a   Schiffer, Lena ^a   Hiss, Marcus ^a   Haller, Hermann ^a   Schiffer, Mario ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Idiopathic membranous glomerulonephritis; Maintenance therapy; Partial remission; Plasma exchange; Rescue therapy; Rituximab

Indexed keywords

ALBUMIN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; GLUCOCORTICOID; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG SCREENING; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PATIENT REFERRAL; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; STANDARD; TREATMENT DURATION; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; GLOMERULONEPHRITIS, MEMBRANOUS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PLASMA EXCHANGE; PROCEDURES; RECURRENT DISEASE;

ADMINISTRATION, ORAL; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PLASMA EXCHANGE; PREDNISOLONE; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RITUXIMAB;

EID: 84983200605     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12545     Document Type: Article

References (43)

1. McQuarrie EP, Mackinnon B, Stewart GA, Geddes CC. Scottish renal biopsy registry membranous nephropathy remains the commonest primary cause of nephrotic syndrome in a northern European Caucasian population. Nephrol Dial Transplant 2010;25:1009-10'.
2. Hanko JB, Mullan RN, O'Rourke DM, McNamee PT, Maxwell AP, Courtney AE. The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant 2009;24:3050-4.
3. Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis 2010;56:157-67.
4. Kuroki A, Shibata T, Honda H, Totsuka D, Kobayashi K, Sugisaki T. Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern Med 2002;41:936-42.
5. Ohtani H, Wakui H, Komatsuda A, Okuyama S, Masai R, Maki N et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant 2004;19:574-9.
6. Kidney disease: improving global outcomes [KDIGO] Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney inter Suppl 2012;2:139-274.
7. 2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011;6:1286-91.
8. Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012;23:1735-43.
9. Bech AP, Hofstra JM, Brenchley PE, Wetzels JF. Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2014;9:1386-92.
10. Skoberne A, Behnert A, Teng B, Fritzler MJ, Pajek J, Lindič J et al. Serum with phospholipase A2 receptor autoantibodies interferes with podocyte adhesion to collagen. Eur J Clin Invest 2014;44:753-65.
11. Ma H, Sandor DG, Beck LH. The role of complement in membranous nephropathy. Semin Nephrol 2013;33:531-42.
12. van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2014;9:1066-73.
13. Laskow DA, Curtis JJ, Luke RG, Julian BA, Jones P, Deierhoi MH et al. Cyclosporine-induced changes in glomerular filtration rate and urea excretion. Am J Med 1990;88:497-502.
14. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 2002;21:923-4.
15. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003;14:1851-7.
16. Ruggenenti P, Chiurchiu C, Abbate M, Perna A, Cravedi P, Bontempelli M et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 2006;1:738-48.
17. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillion JJ et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008;73:117-25.
18. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007;2:932-7.
19. Busch M, Rüster C, Schinköthe C, Gerth J, Wolf G. Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy. Clin Nephrol 2013;80:105-13.
20. Polanco N, Gutierrez E, Covarsí A, Ariza F, Carreño A, Vigil A et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010;21:697-704.
21. Burnstein DM, Korbet SM, Schwartz MM. Membranous glomerulonephritis and malignancy. Am J Kidney Dis 1993;1:5-10.
22. Passerini P, Ponticelli C. Corticosteroids, cyclophosphamide, and chlorambucil therapy of membranous nephropathy. Semin Nephrol 2003;23:355-61.
23. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998;9:444-50.
24. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989;320:8-13.
25. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995;48:1600-4.
26. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001;9:1484-90.
27. Deray G, Benhmida M, Le Hoang P, Maksud P, Aupetit B, Baumelou A et al. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med 1992;17:578-83.
28. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115-23.
29. Giagounidis AA, Anhuf J, Schneider P, Germing U, Sohngen D, Quabeck K et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002;69:95-100.
30. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002;46:2029-33.
31. Johnson PW, Glennie MJ. Rituximab: mechanisms and applications. Br J Cancer 2001;85:1619-23.
32. Beck LH, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011;22:1543-50.
33. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 2014;25:1357-66.
34. Behnert A, Fritzler MJ, Teng B, Zhang M, Bollig F, Haller H. An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor. PLoS ONE 2013;8:e61669.
35. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl 2011;3:85ra46.
36. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010;5:2188-98.
37. Clark WF. Plasma exchange for renal disease: evidence and use 2011. J Clin Apher 2012;27:112-6.
38. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014;371:2277-87.
39. Prunotto M, Carnevali ML, Candiano G, Murtas C, Bruschi M, Corradini E et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010;21:507-19.
40. Bruschi M, Carnevali ML, Murtas C, Candiano G, Petretto A, Prunotto M et al. Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens. J Proteomics 2011;74:2008-17.
41. Ronco P, Debiec H. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J Am Soc Nephrol 2010;21:564-9.
42. Wen M, Kuchle C, Sarkar O, Renders L, Heemann U, Schmaderer C. Plasmapheresis combined with rituximab for refractory idiopathic membranous nephropathy. Int Urol Nephrol 2014;46:847-8.
43. Yokoyama H, Goshima S, Wada T, Takaeda M, Furuichi K, Kobayashi K et al. The short- and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy. Kanazawa Study Group for Renal Diseases and Hypertension. Nephrol Dial Transplant 1999;14:2379-86.